Vertex stocks are down 13% after abandoning phase 2 drug for rare genetic disorders

0
5

Keywords:

Vertex Pharmaceuticals,Alpha-1 antitrypsin deficiency,Stock,Clinical endpoint,NASDAQ:VRTX,Genetic disorder,Clinical trial,Vertex Pharmaceuticals, Alpha-1 antitrypsin deficiency, Stock, Clinical endpoint, NASDAQ:VRTX, Genetic disorder, Clinical trial,,,,,

QU’EN PENSEZ-VOUS?

[comment]

PUB

Laisser un commentaire, votre avis compte!

[gs-fb-comments] [comment-form]